- Home
- SNT vs ZNTL Comparison
SNT vs ZNTL Comparison
Compare SNT & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNT
- ZNTL
- Stock Information
- Founded
- SNT 1965
- ZNTL 2014
- Country
- SNT Canada
- ZNTL United States
- Employees
- SNT N/A
- ZNTL N/A
- Industry
- SNT Telecommunications Equipment
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- SNT Telecommunications
- ZNTL Health Care
- Exchange
- SNT Nasdaq
- ZNTL Nasdaq
- Market Cap
- SNT 95.2M
- ZNTL 105.8M
- IPO Year
- SNT 1993
- ZNTL 2020
- Fundamental
- Price
- SNT $5.04
- ZNTL $1.26
- Analyst Decision
- SNT
- ZNTL Buy
- Analyst Count
- SNT 0
- ZNTL 7
- Target Price
- SNT N/A
- ZNTL $8.60
- AVG Volume (30 Days)
- SNT 110.4K
- ZNTL 1.3M
- Earning Date
- SNT 08-25-2025
- ZNTL 08-08-2025
- Dividend Yield
- SNT N/A
- ZNTL N/A
- EPS Growth
- SNT N/A
- ZNTL N/A
- EPS
- SNT 0.18
- ZNTL N/A
- Revenue
- SNT $36,690,000.00
- ZNTL $26,865,000.00
- Revenue This Year
- SNT N/A
- ZNTL N/A
- Revenue Next Year
- SNT N/A
- ZNTL N/A
- P/E Ratio
- SNT $26.28
- ZNTL N/A
- Revenue Growth
- SNT 8.36
- ZNTL N/A
- 52 Week Low
- SNT $1.40
- ZNTL $1.01
- 52 Week High
- SNT $5.04
- ZNTL $5.44
- Technical
- Relative Strength Index (RSI)
- SNT 70.52
- ZNTL 46.30
- Support Level
- SNT $4.30
- ZNTL $1.13
- Resistance Level
- SNT $4.84
- ZNTL $1.39
- Average True Range (ATR)
- SNT 0.28
- ZNTL 0.11
- MACD
- SNT 0.04
- ZNTL -0.02
- Stochastic Oscillator
- SNT 100.00
- ZNTL 32.93
About SNT Senstar Technologies Ltd.
Senstar Technologies Corp is a provider of comprehensive physical, video, and access control security products and solutions. Its perimeter intrusion detection systems (including fence sensors, buried sensors, and above-ground sensors), intelligent video management, video analytics, and access control offer a comprehensive suite of integrated solutions that reduce complexity, improve performance, and unify support.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.